Fiduciary Alliance LLC lifted its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 117.5% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 366,282 shares of the biopharmaceutical company’s stock after purchasing an additional 197,867 shares during the quarter. Fiduciary Alliance LLC’s holdings in Pfizer were worth $9,959,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of PFE. Horizon Financial Services LLC lifted its stake in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. bought a new stake in shares of Pfizer during the fourth quarter worth $26,000. YANKCOM Partnership bought a new stake in shares of Pfizer during the fourth quarter worth $28,000. HFM Investment Advisors LLC raised its holdings in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares during the period. Finally, Abound Financial LLC bought a new stake in Pfizer in the 4th quarter valued at $31,000. 68.36% of the stock is owned by institutional investors.
Pfizer Trading Down 2.7%
Shares of Pfizer stock opened at $24.05 on Thursday. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The stock has a market cap of $137.07 billion, a P/E ratio of 18.36 and a beta of 0.34. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The business’s 50 day moving average is $26.07 and its 200-day moving average is $26.31.
Pfizer Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 131.30%.
Trending Headlines about Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer won FDA approval for an expanded IBRANCE regimen in metastatic breast cancer, a meaningful commercial and pipeline win for its oncology franchise.
- Positive Sentiment: The company advanced a pediatric pneumococcal “catch-up” vaccine into Phase 3, adding another potential growth catalyst to the pipeline.
- Positive Sentiment: Pfizer declared a $0.43 third-quarter dividend, extending its long streak of quarterly payouts and supporting the stock’s income profile.
- Neutral Sentiment: Pfizer reaffirmed its FY 2026 outlook despite leadership change chatter, which may help reassure investors but does not materially change the near-term growth story.
- Negative Sentiment: Sigvotatug vedotin missed its primary survival goal in Phase 3 lung cancer testing, renewing concerns about Pfizer’s oncology pipeline momentum and contributing to the stock’s weakness. Article Title
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on PFE. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Sunday. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. CICC Research initiated coverage on Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Pfizer in a research report on Monday, June 1st. Finally, HSBC increased their price objective on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.82.
Pfizer Company Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Articles
- Five stocks we like better than Pfizer
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
